VALN Valneva SE - ADRs
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:VLA.
$10.08 +0.10 (1.03%)
As of 03/27/2023 10:43:42 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: France
Country of incorporation:
IPO date: 05/06/2021
Outstanding shares: 69,173,484
Average volume: 3,367
Market cap: $754,163,909
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol: 4581619
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%